Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Apr;32(2):153-161.
doi: 10.1111/tme.12851. Epub 2022 Jan 9.

Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection

Manuel E Baldeón  1 , Augusto Maldonado  2   3 , Miguel Ochoa-Andrade  4 , Carolina Largo  3 , Mónica Pesantez  5 , Marco Herdoiza  5 , Gerardo Granja  4 , Marco Bonifaz  4 , Hugo Espejo  4 , Francisco Mora  4 , Patricio Abril-López  3 , Lady Karen Robles Armijo  6 , Verónica Pacheco  6 , Rafael Salazar  6 , Steffy Reinthaller  6 , Federico Zertuche  7 , Marco Fornasini  1
Affiliations
Randomized Controlled Trial

Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection

Manuel E Baldeón et al. Transfus Med. 2022 Apr.

Abstract

Introduction: South America is one of the regions most affected by the COVID-19 pandemic. Specific and affordable treatments are needed to treat SARS-CoV-2 infection. Evidence regarding the use of convalescent plasma in COVID-19 patients is still limited. We compared the safety and efficacy of COVID-19-convalescent plasma administration as a complement to standard treatment in the early management of patients with moderate SARS-CoV-2 infection.

Methods: We carried out a random double blinded, placebo-controlled trial that compared standard treatment plus convalescent plasma (CP) or plus non-convalescent plasma in the management of COVID-19 patients. The main outcome was survival and secondary endpoints included: length of hospitalisation (LOH), days from treatment to discharge, time to clinical improvement or death within a 28-day period, and adverse reactions to treatment.

Results: Administration of CP with antibodies against SARS-CoV-2 did not affect patient survival, RR = 1.003, 95% CI (0.3938, 2.555). These results led to terminate the RCT prematurely. However, early treatment of COVID-19 patients with CP tended to decrease the LOH while the delay in CP treatment was associated with longer hospitalisation. In addition, delay in CP treatment negatively affected the recovery of the respiratory rate.

Conclusion: Use of CP for the treatment of COVID-19 patients is safe and its early use can decrease the LOH and improve respiratory function. Early administration of antibody-rich CP could contribute to decrease the negative impact of COVID-19 pandemic in patients with impaired immune response.

Keywords: COVID-19; Ecuador; SARS-CoV2; convalescent plasma; passive immunity.

PubMed Disclaimer

References

REFERENCES

    1. Balla M, Merugu GP, Patel M, et al. COVID-19, modern pandemic: a systematic review from front-line health care providers' perspective. J Clin Med Res. 2020;12(4):215-229. https://pubmed.ncbi.nlm.nih.gov/32362969/
    1. Hodgins S, Saad A. Will the higher-income country blueprint for COVID-19 work in low- and lower middle-income countries? Glob Heal Sci Pract. 2020;8(2):136-143. https://pubmed.ncbi.nlm.nih.gov/32522765/
    1. Worldometer. COVID live update: 208,008,480 cases and 4,375,020 deaths from the coronavirus. Worldometer 2021. https://www.worldometers.info/coronavirus/
    1. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21(2):167-179. https://pubmed.ncbi.nlm.nih.gov/33128197/
    1. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: an overview. Eur J Pharmacol. 2020;889:173644-173652. https://pubmed.ncbi.nlm.nih.gov/33053381/

Publication types

LinkOut - more resources